Back to Search
Start Over
4-Demethoxydaunorubicin (Idarubicin) in refractory or relapsed acute leukemias. A pilot study.
- Source :
-
Cancer [Cancer] 1985 Apr 01; Vol. 55 (7), pp. 1452-4. - Publication Year :
- 1985
-
Abstract
- Twenty-five adults with previously treated acute leukemia were treated with 4-demethoxydaunorubicin (Idarubicin) with a daily dose of 8 mg/m2 for 3 days intravenously. Complete remission was achieved in 3 of 18 patients with acute nonlymphoblastic leukemia (ANLL) and 2 of 6 with lymphoblastic leukemia. Complete remissions were observed in two of eight ANLL patients refractory to cytarabine, anthracycline, and m-Amsa (amsacrine), indicating a lack of cross-resistance between these drugs and Idarubicin. The median duration of remission was 8 weeks. The main major toxicity of Idarubicin therapy, severe myelosuppression, cannot be considered a toxic effect because it was desired in this case list. Our preliminary results indicate that Idarubicin has significant activity against refractory adult acute leukemia.
Details
- Language :
- English
- ISSN :
- 0008-543X
- Volume :
- 55
- Issue :
- 7
- Database :
- MEDLINE
- Journal :
- Cancer
- Publication Type :
- Academic Journal
- Accession number :
- 3856461
- Full Text :
- https://doi.org/10.1002/1097-0142(19850401)55:7<1452::aid-cncr2820550705>3.0.co;2-d